WebDec 2, 2016 · IPSS low- or INT-1–risk MDS, chronic myelomonocytic leukemia, or MDS/myeloproliferative neoplasms were treated with standard daily doses of azacitidine … WebNov 4, 2024 · The first, ASTX727-01-B (NCT02103478), included a total of 80 patients with MDS, including those with intermediate-1, intermediate-2, or high-risk IPSS scores, or CMML.6 The second, ASTX727-02 (NCT03306264), included 133 patients with either MDS or CMML, including all French-American-British classification criteria and IPSS intermediate …
Management options for the treatment of benign prostatic …
WebMyelodysplastic syndromes (MDS) are classified using the World Health Organization (WHO) classification system, which was most recently updated in 2016. It divides MDS … WebIntermediate-2 to High risk IPSS score. This project has received funding from the European Union's Horizon 2024 research and innovation programme under grant agreement No. 634789. street teams
Current challenges and unmet medical needs in myelodysplastic …
WebOffer to patients with IPSS Low/Int-1 + symptomatic anaemia or Hb <100 and Nordic score is 0 or 1 Start soon after diagnosis and before established transfusion dependence Maximum 24 week trial - 8 wks initial dose, 8 wks higher dose, 8 wks with GCSF added EPO-alpha 30,000 units/week, rising to 60,000/week WebJan 23, 2024 · A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. WebJul 5, 2024 · IPSS risk statuses at baseline were low, n = 1; Int-1, n = 288; Int-2, n = 355; high, n = 255; and missing, n = 945. Patients with higher-risk MF (Int-2/high risk) according to DIPSS were older, had lower hemoglobin levels, and had higher circulating blast counts (Table 1 ). TABLE 1. Patient characteristics at baseline street teams for bands